Single-use autoinjector for peginterferon-β_1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study

Bibliography

• Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2011;18:69-77
   PubMed Web of Science ®Google Scholar
• Menzin J, Caon C, Nichols C, et al. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm 2013;19(1 Suppl A):S24-40
   PubMed Web of Science ®Google Scholar
• Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence 2010;4:1-9
   PubMed Web of Science ®Google Scholar
• Baker DP, Lin EY, Lin K, et al. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model. Bioconjug Chem 2006;17:179-88
   PubMed Web of Science ®Google Scholar
• Kieseier BC, Calabresi PA. PEGylation of interferon-beta-1a: a promising strategy in multiple sclerosis. CNS Drugs 2012;26:205-14
   PubMed Web of Science ®Google Scholar
• Hu X, Cui Y, Seddighzadeh A, Hung S. Pharmacokinetics of peginterferon beta-1a delivered by single-use autoinjector and pre-filled syringe. Clin Pharmacol Ther 2014;95:S1
   PubMedGoogle Scholar
• Calabresi PA, Kieseier BC, Arnold DL, et al. Pegylated interferon beta-1a in relapsing-remitting multiple sclerosis (ADVANCE): a randomized, phase 3, double-blind study. Lancet Neurol 2014;13(7):657-65
   PubMed Web of Science ®Google Scholar
• Mohr DC, Boudewyn AC, Likosky W, et al. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med 2001;23(2):125-32
   PubMed Web of Science ®Google Scholar
• Ferrando PJ, Lorenzo-Seva U. Acquiescence as a source of bias and model and person misfit: a theoretical and empirical analysis. Br J Math Stat Psychol 2010;63(Pt 2):427-48
   PubMed Web of Science ®Google Scholar
• Wray S, Armstrong R, Herrman C, et al. Results from the single-use autoinjector for self-administration of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis (MOSAIC) study. Expert Opin Drug Deliv 2011;8(12):1543-53
   PubMed Web of Science ®Google Scholar
• Sperling B, Slawka S, Ghaus C, You X. on behalf of the PERSIST study group. Persistence and treatment satisfaction in patients using the AVONEX® PEN™. Poster presented at: The 27th Annual Meeting of the Consortium of Multiple Sclerosis Centers; May 29 – June 1 2013; Orlando, FL, USA. Available from: https://cmscactrims.confex.com/cmscactrims/2013/webprogram/Handout/Paper1375/AVX_Sperling_PERSIST_Interim_Analysis.pdf [Accessed 3 July 2014]
   Google Scholar
• Boeru G, Milanov I, De Robertis F, et al. ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study. Med Devices (Auckl) 2013;6:175-84
   PubMedGoogle Scholar
• Phillips JT, Fox E, Grainger W, et al. An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects. BMC Neurol 2011;11:126
   PubMed Web of Science ®Google Scholar
• Devonshire V, Arbizu T, Borre B, et al. Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study. BMC Neurol 2010;10:28
   PubMed Web of Science ®Google Scholar
• Brochet B, Lemaire G, Beddiaf A; et l’Epicure Study Group. [Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices]. Rev Neurol (Paris) 2006;162(6-7):735-40
   PubMed Web of Science ®Google Scholar
• Mikol D, Lopez-Bresnahan M, Taraskiewicz S, et al. for the Rebiject Study Group. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. Mult Scler 2005;11(5):585-91
   PubMed Web of Science ®Google Scholar
• Lugaresi A, Florio C, Brescia-Morra V, et al. for the BRIDGE study group. Patient adherence to and tolerability of self-administered interferon beta-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. BMC Neurol 2012;12:7
   PubMed Web of Science ®Google Scholar
• D’Arcy C, Thomas D, Stoneman D, Parkes L. Patient assessment of an electronic device for subcutaneous self-injection of interferon beta-1a for multiple sclerosis:an observational study in the UK and Ireland. Patient Prefer Adherence 2012;6:55-61
   PubMed Web of Science ®Google Scholar
• Steinberg SC, Faris RJ, Chang CF, et al. Impact of adherence to interferons in the treatment of multiple sclerosis. A non-experimental, retrospective, cohort study. Clin Drug Investig 2010;30:89-100
   PubMed Web of Science ®Google Scholar
• Tan B, Cai Q, Agarwal S, et al. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther 2011;28:51-61
   PubMed Web of Science ®Google Scholar